Orakl Oncology, a London-based healthtech company, has raised $34 million in Series B funding to expand its artificial intelligence platform that creates virtual patient models for cancer drug testing. The capital injection will enable the startup to scale its technology, expand research and development capabilities, and accelerate clinical trial simulations for pharmaceutical partners.
The funding represents a significant milestone for the company as it seeks to transform how pharmaceutical companies develop and test new oncology treatments. By leveraging artificial intelligence and machine learning, Orakl Oncology has developed a platform that generates sophisticated virtual patient models capable of simulating how different cancer patients might respond to experimental drugs.
Reducing timelines and animal testing
The virtual patient approach offers multiple advantages for the pharmaceutical industry. Drug development traditionally involves lengthy processes that rely heavily on laboratory testing, animal studies, and human clinical trials. By introducing AI-driven virtual patients into this workflow, companies can test multiple drug candidates and dosage strategies in simulated environments before advancing to expensive and time-consuming human trials.
This methodology not only has the potential to accelerate the timeline from drug discovery to market approval but also addresses growing ethical concerns surrounding animal testing in pharmaceutical research. Virtual patient simulations can reduce the number of animals required in preclinical studies while simultaneously improving the quality of data available to researchers making critical decisions about which candidates warrant investment in human trials.
Strategic expansion ahead
The newly secured capital will be deployed across several key areas for the company. Orakl Oncology plans to use the funding to build and scale its virtual-patient platform further, enhancing its computational capabilities and expanding the range of cancer types and patient populations it can model. The company will also strengthen its research and development team to continue innovating its core technology.
Additionally, the investment will support efforts to accelerate clinical trial simulations for pharmaceutical partners. As more major pharmaceutical companies recognize the value of AI-driven drug development tools, demand for robust simulation platforms continues to grow. Orakl Oncology’s expansion comes at a time when the industry is increasingly turning to computational methods to improve efficiency and reduce costs in oncology drug development.
European healthtech momentum
The funding underscores the continued strength of the European healthtech and artificial intelligence sectors. London remains a leading hub for innovation in healthcare technology, attracting significant venture capital investment from both European and international sources. Startups across the continent are increasingly leveraging AI and machine learning to address critical challenges in drug development, patient care, and healthcare delivery.
Orakl Oncology’s progress demonstrates how European companies are positioning themselves at the forefront of technological advancement in pharmaceutical development. As the global healthcare industry seeks new solutions to accelerate innovation while maintaining rigorous safety and efficacy standards, platforms like Orakl’s represent a growing category of European startups attracting substantial investment and driving meaningful change in how medicines are discovered and tested.